Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Thomas E Boyd"'
Autor:
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Publikováno v:
Blood Advances, Vol 1, Iss 2, Pp 122-131 (2016)
Abstract: Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib
Externí odkaz:
https://doaj.org/article/fc19ab6357334e8a83fbb5997926325c
Autor:
Steven E. Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina D. Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah Dreiling, Yeonhee Kim, Siddhartha Mitra, Kanti Rai, John P. Leonard, Richard R. Furman
Publikováno v:
HemaSphere, Vol 2, Iss 3 (2018)
Abstract. Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activit
Externí odkaz:
https://doaj.org/article/6da8a4ddda5d45c196dab088c2d15d99
Autor:
Carlos Becerra, Donald A. Richards, Thomas E. Boyd, Paul Conkling, Hillary H. Wu, Tracy Murray Stewart, Joe Stephenson, Daniel D. Von Hoff, Nicholas J. Vogelzang, Robert A. Casero, Lawrence Garbo, David Smith, Michael L. Fitzgerald, Robert M. Jotte, Laurence J. Marton
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Polyamines are absolutely essential for maintaining tumor cell proliferation. PG-11047, a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine that has demonstrated anticancer activity in cells and animal model
Autor:
Hong Li, David Smith, Thomas E. Boyd, Paul M. Barr, Cindy Yu, Anne Sophie Carret, Steven I. Park, Robert T. Chen, Kathryn S. Kolibaba, Saurabh Chhabra, Tycel Phillips, Edwin C. Kingsley, Paolo Caimi, Elaina M. Gartner
Publikováno v:
Investigational New Drugs
Summary Purpose This first-in-human study evaluated SGN-CD70A, an antibody-drug conjugate (ADC) directed against the integral plasma membrane protein CD70 and linked to a pyrrolobenzodiazepine (PBD) dimer, in patients with relapsed or refractory (R/R
Autor:
Ian W. Flinn, Richard R. Furman, Kanti R. Rai, Nina Wagner-Johnson, Nathan Fowler, Lyndah Dreiling, Steven Coutre, Jeff P. Sharman, Yeonhee Kim, John P. Leonard, Sven de Vos, Marshall T. Schreeder, Siddhartha Mitra, Thomas E. Boyd, Jacqueline C. Barrientos
Publikováno v:
HemaSphere
HemaSphere, Vol 2, Iss 3 (2018)
HemaSphere, Vol 2, Iss 3 (2018)
Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in patie
Autor:
Amy E. DeZern, Marie Puccio-Pick, Joseph G. Jurcic, Thomas E. Boyd, Abderrhamane Laadem, Michael R. Savona, Rami S. Komrokji, David P. Steensma, Jennie Zhang, Jacques Delaunay, Jesus G. Berdeja, Aspasia Stamatoullas, Bond Vo, Guillermo Garcia-Manero, Lionel Ades, Pierre Fenaux, Robert M. Rifkin, Kenneth M. Attie, Odile Beyne-Rauzy, Gautam Borthakur, Mikkael A. Sekeres, Thomas Prebet, Alan F. List
Publikováno v:
The Lancet Haematology. 5:e63-e72
Summary Background Myelodysplastic syndromes are characterised by ineffective erythropoiesis leading to anaemia. Sotatercept (ACE-011) is a novel activin receptor type IIA fusion protein that acts as a ligand trap to neutralise negative regulators of
Autor:
Darren R. Feldman, Thomas E. Boyd, Lawrence H. Einhorn, Lawrence Garbo, Neil C Josephson, Costantine Albany
Publikováno v:
The Oncologist. 23:316-323
BackgroundCytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates. Expression of CD30 has been observed in testicular cancers, and p
Autor:
Yeonhee Kim, Ian W. Flinn, Richard R. Furman, Nina D. Wagner-Johnston, Nathan Fowler, Thomas E. Boyd, Steven Coutre, Ralph V. Boccia, Sven de Vos, Marshall T. Schreeder, John P. Leonard, Kanti R. Rai, Jacqueline C. Barrientos, Jeff P. Sharman, Wayne R. Godfrey
Publikováno v:
Blood Advances. 1:122-131
Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combin
Autor:
Donald A. Richards, Wu Chou Su, Scott P. Myrand, Jin Hyoung Kang, Richard K. Rosenberg, Ji Lin, Sameera R. Wijayawardana, Mary Pinder-Schenck, Scott M. Hynes, Giorgio V. Scagliotti, Aimee Bence Lin, Emily Nash Smyth, David J. Smith, Keunchil Park, Sang We Kim, Thomas E. Boyd, Silvia Novello
Publikováno v:
Investigational New Drugs. 34:625-635
Introduction LY2603618 is a selective inhibitor of checkpoint kinase 1 (CHK1) protein kinase, a key regulator of the DNA damage checkpoint, and is predicted to enhance the effects of antimetabolites, such as pemetrexed. This phase II trial assessed t
Autor:
P. Conkling, Steven D. Gore, Thomas E. Boyd, G. Garcia-Manero, Christopher R. Cogle, Michael R. Savona, Qian Dong, Barry Skikne, Stacey M. Ukrainskyj, Keshava Kumar, Bart L. Scott, Joel Hetzer
Publikováno v:
Leukemia Research. 55:S14-S16